1. Home
  2. LNN vs CTMX Comparison

LNN vs CTMX Comparison

Compare LNN & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lindsay Corporation

LNN

Lindsay Corporation

HOLD

Current Price

$115.44

Market Cap

1.1B

Sector

Industrials

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.25

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNN
CTMX
Founded
1954
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
977.1M
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
LNN
CTMX
Price
$115.44
$3.25
Analyst Decision
Hold
Strong Buy
Analyst Count
1
10
Target Price
$113.00
$12.10
AVG Volume (30 Days)
186.1K
3.2M
Earning Date
04-02-2026
05-08-2026
Dividend Yield
1.35%
N/A
EPS Growth
12.81
N/A
EPS
2.70
N/A
Revenue
$676,368,000.00
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.74
$7.61
P/E Ratio
$41.96
$22.58
Revenue Growth
11.41
N/A
52 Week Low
$97.27
$1.72
52 Week High
$149.56
$8.21

Technical Indicators

Market Signals
Indicator
LNN
CTMX
Relative Strength Index (RSI) 62.12 30.81
Support Level $105.45 $3.06
Resistance Level $118.97 $3.49
Average True Range (ATR) 2.79 0.18
MACD 0.80 -0.03
Stochastic Oscillator 91.19 12.58

Price Performance

Historical Comparison
LNN
CTMX

About LNN Lindsay Corporation

Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: